The world's first preventive treatment for chemotherapy bone marrow protection has been approved

Recently, G1 Therapeutics announced that its main product, Trilaciclib (trade name: COSELA), has been approved by the U.S. FDA to prevent bone marrow inhibition in adult patients with diffused stage small cell lung cancer due to platinum-based etoposide or topological tetosoma chemotherapy.Trilaciclib is known to be a "First-in-Class" small molecule short-acting CDK 4/6 inhibitor discovered and developed by G1, is a comprehensive bone marrow protection agent, has been awarded the FDA priority review qualification and breakthrough therapy. Trilaciclib's approval means it is the world's first and only product to be given preventively during chemotherapy to protect bone marrow and immune system function.In June 2020, G1 signed a cooperation agreement with Grigg Ingham to sell Trilaciclib in markets such as the United States. In August, Synth Pharmaceuticals reached an exclusive licensing agreement with G1 to develop and commercialize all of Trilaciclib's adaptations in Greater China and will participate in its clinical trials around the world. According to the website of the Drug Review Center (CDE) of the State Drug Administration of China, the application for a solid tumor-related clinical trial for the high myeloid toxicity chemotherapy program jointly declared by Synthe and G1s for Trilacic Therapeuticlib was approved in January this year.Improving the prognostication of chemotherapy patients, the market is promisingin China, more than 4 million new cancer cases occur each year, more than half of cancer patients may need medication, and chemotherapy remains the most basic treatment for drug treatment.Chemotherapy drugs do not distinguish between healthy cells and cancer cells, so they affect to some extent white blood cells, red blood cells and plate plates produced in the bone marrow, leading to a side effect of bone marrow inhibition. In the event of bone marrow inhibition, resuscitation interventions, such as blood transfusions or infusions of growth factors/plateplates, are usually required, and may also lead to reduced or discontinued chemotherapy, affecting the patient's survival benefits.The preventive use of Trilaciclib before chemotherapy can briefly block bone marrow cells in the G1 stage of the cell cycle, significantly reduce the damage of chemotherapy drugs to bone marrow cells, protect bone marrow cells and immune system function, its significance not only improves the quality of life of patients, but also can increase the number of chemotherapy cycles in some patients, improve the overall survival benefits of patients with resoccurring tumors such as small cell lung cancer (SCLC), triple negative breast cancer (TNBC).At the San Antonio Breast Cancer Forum (SABCS) in December, a Phase II clinical study submitted by G1 called "Trilaciclib and the Gissithambin/Capra Chemotherapy Programme (GC Program) for the treatment of relapsed or metastasis tri-negative breast cancer" raised academic concerns. The total survival time (OS) of patients who could be used increased from 12.6 months to 19.8 months (p<0.0001) compared to the mere use of the Gissythabin/carpentrina chemotherapy program. The improved OS data has brought a clean stream of the current generally poor treatment of triple-negative breast cancer, with G1 shares up more than 50 per cent since the December announcement, in the same way that clinical experts and investors have expected. Based on the findings, G1 will launch Trilaciclib's key research on mTNBC in the first half of this year.Trilaciclib is likely to complement basic chemotherapy in the future and will reach a wide range of patients, with analysts estimating peak sales of the drug at more than $2 billion, given the potential for both the domestic whitening market and the TNBC market. (
Sina Pharmaceutical News
)